DBV Technologies anticipates filing its Biologics License Application for the VIASKIN Peanut Patch in children aged 4 through 7 years in Q3 2026. The company received guidance to reformat data without needing to conduct additional clinical trials.
DBV Technologies anticipates filing its Biologics License Application for the VIASKIN Peanut Patch in children aged 4 through 7 years in Q3 2026. The company received guidance to reformat data without needing to conduct additional clinical trials.